Maximillian A. Weigelt,1,* Stephanie A. McNamara,1 Daniela Sanchez,2 Penelope A. Hirt,1 and Robert S. Kirsner1
1Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
2Boston University School of Medicine, Boston, Massachusetts, USA.
Significance: Biofilms in vivo are small densely packed aggregations of microbes that are highly resistant to host immune responses and treatment. They attach to each other and to nearby surfaces. Biofilms are difficult to study and identify in a clinical setting as their quantification necessitates the use of advanced microscopy techniques such as confocal laser scanning microscopy. Nonetheless, it is likely that biofilms contribute to the pathophysiology of chronic skin wounds. Reducing, removing, or preventing biofilms is thus a logical approach to help clinicians heal chronic wounds.
Recent Advances: Wound care products have demonstrated varying degrees of efficacy in destroying biofilms in in vitro and preclinical models, as well as in some clinical studies.
Critical Issues: Controlled studies exploring the beneficial role of biofilm eradication and its relationship to healing in patients with chronic wounds are limited. This review aims to discuss the mode of action and clinical significance of currently available antibiofilm products, including surfactants, dressings, and others, with a focus on levels of evidence for efficacy in disrupting biofilms and ability to improve wound healing outcomes.
Future Directions: Few available products have good evidence to support antibiofilm activity and wound healing benefits. Novel therapeutic strategies are on the horizon. More high-quality clinical studies are needed. The development of noninvasive techniques to quantify biofilms will facilitate increased ease of research about biofilms in wounds and how to combat them.
Keywords: biofilm, wound, healing, treatment, therapy
Rahmi Dianty1,2 , Junki Hirano1,2 , Itsuki Anzai1,3 , Yuta Kanai1,4 , Tsuyoshi Hayashi5 , Masae Morimoto6 , Chikako Kataoka-Nakamura6 , Sakura Kobayashi5 , Kentaro Uemura1,2 , Chikako Ono1,2 , Tokiko Watanabe1,3,7 , Takeshi Kobayashi1,4,7 , Kosuke Murakami5 , Kenji Kikuchi8 , Kunimoto Hotta8 , Toshikazu Yoshikawa8 , Shuhei Taguwa1,2,7 * and Yoshiharu Matsuura1,2,7 *
1 Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan, 2Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, 3Laboratory of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, 4Laboratory of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, 5Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan, 6Innovative Vaccine Research and Development Center, The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan, 7 Center for Advanced Modalities and DDS, Osaka University, Osaka, Japan, 8Louis Pasteur Center for Medical Research, Kyoto, Japan
It is essential to employ efficient measures to prevent the transmission of pathogenic agents during a pandemic. One such method involves using hypochlorous acid (HClO) solution. The oxidative properties of HClO water (HAW) can contribute to its ability to eliminate viral particles. Here, we examined a highly purified slightly acidic hypochlorous acid water (Hp-SA-HAW) obtained from the reverse osmosis membrane treatment of an electrolytically-generated SA-HAW for its anti-viral activity and mode of action on viral proteins. Hp-SA-HAW exhibited broad-spectrum antiviral effects against various viruses, including adenovirus, hepatitis B virus, Japanese encephalitis virus (JEV), and rotavirus. Additionally, Hp-SA-HAW treatment dose-dependently resulted in irreversibly aggregated multimers of the JEV envelope and capsid proteins. However, Hp-SA-HAW treatment had no discernible effect on viral RNA, indicating that Hp-SA HAW acts against amino acids rather than nucleic acids. Furthermore, Hp-SA-HAW substantially reduced the infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the ancestral variant and other multiple variants. Hp-SA-HAW treatment induced the aggregation of the SARS-CoV-2 spike and nuclear proteins and disrupted the binding of the purified spike protein of SARS-CoV-2 to human ACE2. This study demonstrates that the broad-spectrum virucidal activity of highly purified HClO is attributed to viral protein aggregation of virion via protein oxidation.
KEYWORDS
hypochlorous acid, virucide, SARS-CoV-2, oxidation, protein aggregation
This article is excerpted from the 《Frontiers in Aging》 by Wound World
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。